Advances in drug resistance of osteosarcoma caused by pregnane X receptor

Abstract

Osteosarcoma (OS) is a prevalent malignancy among adolescents, commonly manifesting during childhood and adolescence. It exhibits a high degree of malignancy, propensity for metastasis, rapid progression, and poses challenges in clinical management. Chemotherapy represents an efficacious therapeutic modality for OS treatment. However, chemotherapy resistance of OS is a major problem in clinical treatment. In order to treat OS effectively, it is particularly important to explore the mechanism of chemotherapy resistance in OS.The Pregnane X receptor (PXR) is a nuclear receptor primarily involved in the metabolism, transport, and elimination of xenobiotics, including chemotherapeutic agents. PXR involves three stages of drug metabolism: stage I: drug metabolism enzymes; stage II: drug binding enzyme; stage III: drug transporter.PXR has been confirmed to be involved in the process of chemotherapy resistance in malignant tumors. The expression of PXR is increased in OS, which may be related to drug resistance of OS. Therefore, wereviewed in detail the role of PXR in chemotherapy drug resistance in OS.

Keywords:

• Osteosarcoma
• PXR
• drug resistance
• drug metabolizing enzyme
• drug binding enzyme
• drug transporter

Authors’ contributions

KM conceived and coordinated the study, CL designed the study. ZT analyzed the literature, ZR wrote the paper. JW did the database search. ZR and JW contribute equally to this study, they revised the paper and shared co-corresponding author.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data Availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

This study was supported by Science project of Hunan Provincial Health Commission, No.B202304089304.